webleads-tracker

EFPIA

Polaris : Important Compliance and Transparency Updates

Andy Bender, Founder and President, Polaris Polaris is pleased to provide a quarterly update of compliance and transparency developments and changes that took place in Q2 that may effect your business: AMERICAS TRANSPARENCY GLOBAL TRANSPARENCY PRE-NOTIFICATION OUS ABAC/FCPA PRIVACY/DATA PROTECTION US REGULATORY, ANTI-KICKBACK, FALSE CLAIMS AND CIAs FAIR MARKET VALUE

Read More »

Webinar today 12/07 19h | EFPIA Disclosure: Rights and requirements for Consent Management

Sunshine Act

  With regard to the EFPIA disclosure, privacy laws in some countries require consent given by the HCP for individual disclosure. This educational webinar will provide an overview of transparency, compliance, and anti-corruption requirements in the European Union. Example topics covered by the experts in this webinar include: Differences between EFPIA Industry Disclosure Code and Transparency Law Country specific considerations e.g In Denmark reporting obligations are on the HCP. Requirements of HCP Consent and overlap with privacy laws Anti-corruption laws and practical considerations Best practices in Physician Consent Management Date: 12th July 2016 Time: 12 PM (EST) – 6 PM (UTC+1 London) – 19h (UTC+2 …

Read More »

EFPIA Transparency Report 2016: Insights on the First Complete Cycle

The final deadline for publication and submission of reports of transparency disclosures required by the European Federation of Pharmaceutical Industry Associations (EFPIA) arrived on June 30, 2016. Companies have now completed publication of all 2015 ‘transfers of value’ (ToV) to healthcare professionals (HCPs) within the 31 countries that signed on to this initiative. Several changes to the requirements have already been made, and questions and concerns remain for amendments likely to be implemented later this year. Additional changes to the requirements are anticipated later this year. Several countries have lobbied to have local government requirements replace the EFPIA reporting requirement, …

Read More »

Publications EFPIA : les données UK sont disponibles sur la plateforme commune de l’ABPI

Sunshine Act

The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines. It is a relationship that we are proud of. At the core of the relationship is sharing knowledge to improve outcomes for patients. We want to ensure that patients and others have confidence that this relationship is open and transparent and this is why the pharmaceutical industry is taking the lead on disclosing details of payments and other benefits in kind made by industry to HCPs and HCOs. This information will be …

Read More »

Publications EFPIA : 23 filiales de Bayer

Sunshine Act

Conformément au code de transparence de l’EFPIA, Bayer s’engage à publier tous les transferts de valeurs relatif au développement et à la commercialisation de produits pharmaceutiques sous prescription médicale en lien avec les professionnels et les organismes de santé. Une partie des Transferts de Valeurs publiés pour l’année 2015 à titre d’exemple : FRANCE ITALIE Recherche et Développement 6.011.239 €  4.867.693 € Professionnels de santé (HCP) 4.718.348 €  6.074.765 € Organismes de santé (HCO) 3.374.913 €  12.784.337 € TOTAL 14.104.500 €  23.727.796 € Pour consulter les Transferts de Valeurs des 23 filiales de Bayer soumises à l’EFPIA : Austria Bulgaria …

Read More »

NHS staff shun ‘transparency register’ listing payments from drugs firms

The identities of hundreds of NHS doctors and officials receiving payments from drugs firms are likely to be kept secret despite the publication of a new “transparency register” this week, the Telegraph can disclose. Up to half of medics and other health service staff working for pharmaceutical companies alongside their day jobs have refused permission for their names to be included in a new online database. The publication of the register follows recent controversy over the practice of NHS staff being paid by drugs companies, with the industry claiming the data would allow the public to see which officials were …

Read More »